drugset / Trial / NCT06843551

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

NCT06843551

Phase 2 Recruiting 20 enrolled Benjamin Spieler Agenus Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.

Timeline

Start
2025-06-18
Primary completion
2030-08-01
Completion
2030-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Balstilimab Monoclonal antibody 240 mg Intravenous
Subject Botensilimab Monoclonal antibody 75 mg Intravenous